Update BUY

Target price: EUR 4.70

Overview

Industry:	IT Services & S	Software
Country:	(Germany
ISIN:	DE0007	7008906
Reuters:	R	TCG.DE
Bloomberg:		RTC GR
Website:	www.rea	ltech.de
Last price:		4.24
	High	Low
Price 52 W.:	7.18	3.95
Market cap. (EURm)		22.81
Number of shares (r	n)	5.39

Shareholders

Daniele Di Croco	16.44%
Rainer Schmidt	14.22%
Peter Stier	13.84%
BW-Versorgungsanstalt	5.39%
Free float	50.11%

Performance

4 weeks	-2.03%
13 weeks	-11.30%
26 weeks	-25.48%
52 weeks	-23.49%
YTD	-22.17%

Dividend		
	in EUR	in %
2008	0.50	11.81%
2009	0.50	11.81%
2010	0.00	0.00%
2011	0.30	7.08%

52-Week Chart



Analyst

Dr. Norbert Kalliwoda Email: nk@kalliwoda.com Phone: +49 69 97 20 58 53

REALTECH AG

Weaker than expected 9M/12 sales; PT down

- Apart from sales, which in our view disappointed, REALTECH's 9M/12 figures showed a solid performance. While total revenues increased by 1.8% y-o-y to €29.1m, operating income improved from €-38k in 9M/11 to €-10k. Net income deteriorated from €464k to €-616k which however stemmed from a one-off profit of €1.1m in 9M/11.
- In 9M/12, the main growth driver was again the Consulting segment (+4.5% y-o-y to €20.2m), which benefitted from improved capacity utilization and new contracts e.g. for SAP Mobile. In the Asia/Pacific region, which was particularly affected by a strong recovery of sales in Japan (+84% to €5m) after the Fukushima catastrophe in H1/11, REALTECH registered a growth of 52.8% y-o-y to €7.3m. This and a higher gross margin, which stemmed from higher utilization of consultants, were the main reasons, why EBIT improved y-o-y.
- Due to a weaker net income y-o-y and an increase of working capital the operating cash flow deteriorated from €5.3m in 9M/11 to €-776k. Together with cash outflows from investing and financing activity REALTECH paid out €1.6m in dividends for 2011 this resulted in a reduction of the cash position by €2.8m to €10.4m. As liquid funds remaind higher than interest-bearing debt, the company's net gearing amounted to -22.7% at the end of September 2012.

As 9M/12 sales came in below our estimates, which in our opinion was caused by pricing pressure, we have adjusted our revenue forecasts for 2012 and beyond by c. 9%. Consequently, the price target goes down from previously \notin 5.00 to \notin 4.70; however does not affect our BUY recommendation. We still think that fiscal-year 2013 will be better for REALTECH and that risks remain low due to the company's high net cash position.

Key Figures

ing ing an ob						
EURm	2008	2009	2010	2011	2012E	2013E
Net sales	70.82	61.68	39.50	39.18	41.14	47.72
EBITDA	8.04	3.71	5.33	1.41	1.31	2.46
EBIT	7.03	2.58	4.18	0.17	0.01	0.95
Net income	5.70	1.20	-1.37	0.81	-0.18	0.48
EPS	1.09	0.23	-0.26	0.15	-0.03	0.09
BVPS	5.42	5.26	4.60	4.77	4.72	4.81
RoE	20.01%	4.27%	-5.26%	3.22%	-0.71%	1.88%
EBIT margin	9.92 %	4.18 %	10.58 %	0.43 %	0.02 %	2.00 %
P/E	3.90	18.59	neg.	28.19	neg.	47.26
P/BVPS	0.78	0.80	0.92	0.89	0.90	0.88
EV/EBITDA	2.18	4.72	3.28	12.44	13.37	7.10

Content

 Company profile	
 3 Valuation	
 9M 2012 financial results	5
 6 Stock and shareholder structure 7 Profit and loss statements 	6
7 Profit and loss statements	9
	10
8 Balance sheets	11
	12
9 Cash flow statements	13
10 Financial ratios	13

1 Company profile

REALTECH AG is one of the leading German IT consultancies. The company was founded in 1994 in Walldorf, near Heidelberg, and has been listed on the Frankfurt stock exchange since 1999. Apart from Germany, REALTECH also has operations in other European countries, Asia/Pacific and North America. At the end of September 2012, it had 341 employees, thereof 249 in Germany.

In the past, the fast progress of IT technology has resulted in a high number of enterprise application systems as well as a diverse, heterogenic IT landscape. Especially, non-integrated standalone systems, proprietary software and isolated applications have led to significant integration deficits, which at company level have limited cross-functional work processes and complicated information supply for disposition tasks. REALTECH's IT consulting services can facilitate an instant integration of customers and suppliers into the value chain, which in turn can prevent media disruption and redundancies and allow new forms of intercompany collaboration. REALTECHs's products allow IT departments or IT outsourcers to run a variety of applications and IT systems securely and efficiently and reduce IT costs significantly.

2 SWOT Analysis

Strength

- Due to the long-standing co-operation with and proximity to SAP REALTECH has a know-how edge when it comes to SAP applications.
- A unique selling point in the area of Consulting is the combination of SAP knowledge as well as supplemental business and strategic consulting. Thus, REALTECH can provide a fast and long-term project success. Due to the partnership, which is also valid in foreign markets, it is also possible to integrate international locations into a comprehensive IT landscape.
- theGuard! product family is an internationally unique software portfolio for the monitoring and the secure operation of IT systems for company-wide use. In Europe, REALTECH is the largest manufacturer of IT service management solutions. Unique selling points are the close connection of all disciplines, the centralized storage according to standards such as ITIL as well as the application in small companies, simultaneously guaranteeing future scalability of product use.

Opportunities

- **The OEM contract with SAP** in the area of IT infrastructure management as well as expansion of SAP solutions should all contribute to internationalization and growth of high-margin sales.
- Due to standardization of the consulting portfolio. product sales in new countries and third-party sales of the enterprise solution for SAP ByDesign, there is an opportunity to generate high scale effects.
- A higher demand for change management support, driven by the trend to use external suppliers in order to further develop SAP software should lead to additional sales.
- IT systems increasingly constitute the basis for cross-departmental business processes, which lead to a higher level of complexity. Thus, there is higher demand for REALTECH's solutions for flexible, automated and failsafe systems.

Weaknesses

- Concentration on SAP solutions means a high dependence on market acceptance and SAP's existing customers. Thus, there is high business risk. However, a wide geographic diversification with branches in Europe, Asia and the US and cross-industry product distribution in over 25 countries reduce the above-mentioned risk.
- **There is strong competition** in the area of Consulting.

Threats

- The ongoing consolidation within the IT industry can intensify competition through new or stronger competitors. This would result in a loss of revenues or lower prices.
- A lack of qualified personnel caused by a structural shortage of supply in the industry would make it more difficult for the company to become aware of its opportunities. This is being counteracted by REALTECH's reputation as an attractive training provider, which stems from the company's SAP knowhow.

3 Valuation

In order to value REALTECH, we have used our DCF model, which derives a 12-months price target for the stock of ≤ 4.70 . Compared to the current market level, this corresponds to an upside of 11.0%.

DCF model

WACC assumptions	
Growth assumptions	
Long-term grow th rate	2.0%
Assimiliation phase (from 2015)	5 years
Sales grow th at the beginning	13.3%
Margin development (p.a)	-1 BP
Equity	
Risk-free rate	2.3%
Market risk premium	6.0%
Beta	1.20
Equity costs	9.5%
Debt costs	
Debt costs (before tax)	6.0%
Tax rate on interest	30.0%
Debt costs (after tax)	4.2%
Equity	100
Debt	0
Gearing	0.0%
WACC	9.50%

Discounted Cash Flow Model (Basis 11/2012)

					Phase 1				
in EURm	2012E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Netsales	41.14	47.72	54.88	62.18	68.39	73.52	77.20	79.51	81.10
(y-o-y change)	5.0%	16.0%	15.0%	13.3%	10.0%	7.5%	5.0%	3.0%	2.0%
EBIT	0.01	0.95	1.65	2.49	3.08	3.23	3.40	3.42	3.51
(EBIT margin)	0.0%	2.0%	3.0%	4.0%	4.5%	4.4%	4.4%	4.3%	4.3%
NOPLAT	0.01	0.67	1.15	1.74	2.15	2.26	2.38	2.39	2.46
+ Depreciation	1.30	1.51	1.73	1.97	2.16	2.32	2.44	2.51	2.56
= Net operating cash flow	1.31	2.18	2.89	3.71	4.32	4.59	4.82	4.91	5.02
- Total investments (Capex and WC)	-1.90	-2.36	-2.62	-2.85	-2.99	-3.10	-3.14	-3.14	-3.15
Capital expenditure	-1.82	-2.08	-2.32	-2.55	-2.73	-2.88	-2.98	-3.04	-3.08
Working capital	-0.08	-0.28	-0.30	-0.31	-0.26	-0.22	-0.15	-0.10	-0.07
= Free cash flow (FCF)	-0.60	-0.18	0.27	0.85	1.32	1.49	1.68	1.77	1.87
PV of FCF's	-0.59	-0.16	0.22	0.64	0.91	0.93	0.96	0.93	0.89

Fair value per share in € (in 12 months)	4.70
Fair value per share in € (today)	4.29
Debt ratio	0.0%
Equity ratio	100.0%
Debt costs after tax	4.2%
Tax rate	30.0%
Debt costs before tax	6.0%
Equity costs	9.5%
WACC	9.5%
	5.39
Number of shares outstanding (m)	5.39
Shareholder value	23.11
+ Investments / - Minorities	-1.14
+ Net cash / - net debt	5.31
Enterprise value (EV)	18.93
PV of FCFs in terminal period	14.20
PV of FCFs in explicit period	4.73

				inal EBIT ma	- gin		
	1.3%	2.3%	3.3%	4.3%	5.3%	6.3%	7.3%
6.5%	3.34	4.90	6.47	8.04	9.60	11.17	12.73
7.5%	2.95	4.13	5.32	6.51	7.70	8.88	10.07
8.5%	2.67	3.60	4.53	5.46	6.39	7.32	8.26
9.5%	2.45	3.20	3.95	4.70	5.45	6.20	6.95
10.5%	2.28	2.89	3.51	4.12	4.74	5.35	5.96
11.5%	2.14	2.65	3.16	3.67	4.18	4.69	5.20
	7.5% 8.5% 9.5% 10.5%	6.5% 3.34 7.5% 2.95 8.5% 2.67 9.5% 2.45 10.5% 2.28	6.5% 3.34 4.90 7.5% 2.95 4.13 8.5% 2.67 3.60 9.5% 2.45 3.20 10.5% 2.28 2.89	6.5% 3.34 4.90 6.47 7.5% 2.95 4.13 5.32 8.5% 2.67 3.60 4.53 9.5% 2.45 3.20 3.95 10.5% 2.28 2.89 3.51	6.5% 3.34 4.90 6.47 8.04 7.5% 2.95 4.13 5.32 6.51 8.5% 2.67 3.60 4.53 5.46 9.5% 2.45 3.20 3.95 4.70 10.5% 2.28 2.89 3.51 4.12	6.5% 3.34 4.90 6.47 8.04 9.60 7.5% 2.95 4.13 5.32 6.51 7.70 8.5% 2.67 3.60 4.53 5.46 6.39 9.5% 2.45 3.20 3.95 4.70 5.45 10.5% 2.28 2.89 3.51 4.12 4.74	6.5% 3.34 4.90 6.47 8.04 9.60 11.17 7.5% 2.95 4.13 5.32 6.51 7.70 8.88 8.5% 2.67 3.60 4.53 5.46 6.39 7.32 9.5% 2.45 3.20 3.95 4.70 5.45 6.20 10.5% 2.28 2.89 3.51 4.12 4.74 5.35

Source: Dr. Kalliwoda Research GmbH

4 9M 2012 financial results

Revenues

In 9M/12, REALTECH generated total sales of \notin 29.1m, which were 1.8% higher y-o-y. With +4.5% to \notin 20.2m, the Consulting segment, which benefitted from a higher utilisation of consultants and new contracts e.g. for SAP Mobile, contributed most to top-line growth. Due to lower sales of software licenses revenues of the high-margin Software segment (-3.8% y-o-y to \notin 8.9m) deteriorated y-o-y, which led to a decrease of the segment's gross margin from 85.9% to 84.7%. In terms of regional sales, all but USA and Asia/Pacific reported lower revenues y-o-y. Asia/Pacific, whose share in REALTECH's total sales went up from 16.7% in 9M/11 to 25.1%, benefitted especially from a strong recovery in Japan after the Fukushima catastrophe in H1/11.

9M/12 vs. previous year

in EURm	9M 2012	9M 2011	change (%)
Net sales	29.09	28.57	1.8%
EBITDA	0.92	0.42	119.8%
EBITDA margin	3.2%	1.5%	
EBIT	-0.01	-0.36	-97.3%
EBIT margin	0.0%	-1.3%	
Net income	-0.62	0.46	-232.8%
Net margin	-2.1%	1.6%	

Source: Company information, Dr. Kalliwoda Research GmbH


Sales and gross margins according to segments

Sales and EBIT margins a	ccording t <u>o se</u>	gments 9M/1	2 v	s. 9M/11	s. 9M/11
	9M 2012	9M 2011	_		9M 2012
Consulting				Group	Group
Sales €m	20.20	19.33		Total sales	Total sales 29.09
share in total sales	69.5%	67.7%		change y-o-y	change y-o-y 1.8%
Gross margin	28.4%	21.0%			
Software					
Sales €m	8.88	9.23			
share in total sales	30.5%	32.3%			
Gross margin	84.7%	85.9%			
Germany				USA	USA
Sales €m	19.10	20.70		Sales €m	
share in total sales	65.7%	72.5%		share in total sales	share in total sales 7.6%
RoE (Portugal, Nordic)			1	Asia/Pacific	Asia/Pacific
Sales €m	0.50	1.00		Sales €m	Sales €m 7.29
share in total sales	1.7%	3.5%	_	share in total sales	share in total sales 25.1%

Source: Company information, Dr. Kalliwoda Research GmbH

Profitability

8



Share in sales 9M/12 vs. 9M/11

Source: Company information, Dr. Kalliwoda Research GmbH

Although REALTECH's EBIT improved y-o-y, the net income was lower than in 9M/11. The operating income was positively affected by a higher gross margin, which stemmed from an improved utilization of consultants. The good performance of the Consulting segment offset a weaker gross margin in the Software unit, which resulted from lower sales of software licenses. Due to a one-off gain in 9M/11 (≤ 1.1 m) resulting from the reversal of the loss albwance on a claim from a loan to REALTECH Italy net income in 9M/12 decreased y-o-y.

Balance Sheet and Cash Flow

At the end of 9M/12, the most important positions on REALTECH's balance sheet were (1) equity of \notin 23.4m (2) PP&E of \notin 13.4m and (3) trade receivables of \notin 11.3m. As of 30 September 2012, the company had interest-bearing debt of \notin 6m (short- and long-term finance lease obligations) and liquid funds (cash plus financial assets) of \notin 11.3m. Thus, net cash amounted to \notin 5.3m.

Due to a net loss and increase of working capital by €1.6m (9M/11: reduction of €5.1m) REALTECH's operating cash flow deteriorated from €5.3m to €-76k. Together with a cash outflow from investing of €558k and financing of €1.6m, which stemmed from adividend payout of €0.30 per share, this led to a total cash outflow of €2.8m in 9M/12.

5 Outlook

9

In the recent past, REALTECH has optimized its service portfolio, which showed positive effects in 9M/12 and led to first orders for new themes e.g. for SAP Mobile. The company has put a strong focus on trend themes such as real-time processing and analysis of large data volumes (In-Memory-Computing), mobile access to data and cloud applications, all around products of its partner SAP AG (e.g. SAP HANA solution). As enterprise processes are increasingly based on software and corporate customers need IT know-how, REALTECH expects to grow its Consulting business strongly in the next years.

In the Software segment, management's strategic objective is to become a leading player in the IT service management market. In order to achieve that, REALTECH plans to expand internationally and develop new products e.g. a new cloud-based applications, which are supposed to expand the company's integrated theGuard! portfolio significantly.

As 9M/12 revenues did not meet our expectations, we have lowered our top-line forecasts for fiscal-year 2012 and beyond. On the EBIT level, we are slightly more conservative than management, who guide for positive operating income. We see business suffering from pricing pressure and cautious customers, which limit their investments due to the European debt crisis and uncertain economic situation.

Our forecasts 2012E-14E

· 2014E		
2012E	2013E	2014E
41.14	47.72	54.88
1.31	2.46	3.38
3.2%	5.2%	6.2%
0.01	0.95	1.65
0.0%	2.0%	3.0%
-0.18	0.48	0.97
-0.4%	1.0%	1.8%
	2012E 41.14 1.31 3.2% 0.01 0.0% -0.18	2012E 2013E 41.14 47.72 1.31 2.46 3.2% 5.2% 0.01 0.95 0.0% 2.0% -0.18 0.48


Source: Dr. Kalliwoda Research GmbH

Sales estimates according to segments 2012E-14E


Sales estimates according to segments 2012E-2014E				
in EURm	2012E	2013E	2014E	
Consulting	28.55	33.16	38.17	
change y-o-y	8.0%	16.1%	15.1%	
share in total sales	69.4%	69.5%	69.6%	
Software	12.59	14.56	16.70	
change y-o-y	-1.2%	15.7%	14.7%	
share in total sales	30.6%	30.5%	30.4%	
Total sales	41.14	47.72	54.88	

Source: Dr. Kalliwoda Research GmbH

6 Stock and shareholder structure



Shareholder Structure



7 Profit and loss statements

rofit and loss statement - Realtech AG

	Fiscal year					
n EURm	2008	2009	2010	2011	2012E	20135
Sales split	2008	2009	2010	2011	2012E	20135
Consulting	54.05	49.53	26.60	26.43	28.55	33.16
Software	16.77	12.15	12.90	12.74	12.59	14.56
Net sales	70.82	61.68	39.50	39.18	41.14	47.72
Change in inventories	0.00	0.00	0.00	0.00	0.00	0.00
Total Output	70.82	61.68	39.50	39.18	41.14	47.72
Cost of goods sold	-42.90	-39.69	-20.39	-20.99	-22.04	-25.57
Gross profit	27.92	21.99	19.11	18.18	19.09	22.1
Other operating income	2.53	2.04	2.04	1.05	1.07	1.09
Distribution costs	-9.16	-8.48	-6.48	-7.61	-6.99	-8.06
Depreciation & Amortization	-1.01	-1.13	-1.15	-1.24	-1.30	-1.5
Administration costs	-7.05	-6.68	-4.66	-4.97	-5.14	-5.87
R&D costs	-4.62	-3.85	-3.62	-4.30	-4.11	-4.68
Other operating expenses	-1.57	-1.31	-1.05	-0.94	-2.60	-2.16
EBIT	7.03	2.58	4.18	0.17	0.01	0.9
Net financial results	1.47	-0.15	-0.20	-0.21	-0.27	-0.26
EBT	8.50	2.43	3.98	-0.04	-0.26	0.69
Income taxes	-2.69	-1.12	-2.38	-0.17	0.08	-0.2
Minority interests	-0.11	-0.10	-0.01	-0.09	0.00	0.00
Net income / loss	5.70	1.20	1.59	-0.30	-0.18	0.48
EPS	1.09	0.23	-0.26	0.15	-0.03	0.09
DPS	0.50	0.50	0.00	0.30	0.00	0.00
Change y-o-y						
Net sales	n.a	-12.92%	-35.95%	-0.82%	5.00%	16.00%
Total Output	n.a	-12.92%	-35.95%	-0.82%	5.00%	16.00%
Cost of goods sold	n.a	-7.49%	-48.61%	2.94%	5.00%	16.00%
Gross profit	n.a	-21.25%	-13.10%	-4.83%	5.00%	16.00%
Other operating income	n.a	-19.49%	-0.01%	-48.69%	2.00%	2.00%
Distribution costs	n.a	-7.41%	-23.61%	17.53%	-8.16%	15.32%
Depreciation & Amortization	n.a	11.87%	1.54%	7.64%	5.00%	16.00%
Administration costs	n.a	-5.34%	-30.14%	6.64%	3.35%	14.14%
R&D costs	n.a	-16.80%	-5.78%	18.64%	-4.29%	13.68%
Other operating expenses	n.a	-16.89%	-20.09%	-10.58%	178.29%	-16.88%
EBIT	n.a	-63.32%	62.18%	-95.98%	-95.11%	11500.00%
Net financial results	n.a	-110.19%	30.79%	4.71%	31.58%	-3.70%
EBT	n.a	-71.43%	64.12%	-100.93%	605.55%	-365.26%
Income taxes	n.a	-58.24%	111.93%	-92.74%	-145.51%	-365.26%
Net income / loss	n.a	-78.91%	32.40%	-118.99%	-39.82%	-365.26%
EPS	n.a	-79.00%	-213.32%	-158.20%	-122.48%	-365.26%
DPS	n.a	0.00%	-100.00%	n.a	-100.00%	n.a
Share in total sales	400.00.0/	100.00.00	100.00.0/	100.00.0/	100.00.0/	400.000
Vet sales Total Output	100.00 %	100.00 %	100.00 %	100.00 %	100.00 %	100.00 %
Total Output Cost of goods sold	179.30 %	156.14 % -100.48 %	100.00 % -51.63 %	99.18 %	104.14 %	120.81 %
Gross profit	-108.62 %		-51.63 % 48.37 %	-53.59 %	-53.59 %	-53.59 %
Other operating income	70.68 % 6.41 %	55.66 % 5.16 %	48.37 % 5.16 %	46.41 % 2.67 %	46.41 % 2.59 %	46.41 % 2.28 %
Distribution costs	-23.19 %	-21.47 %	-16.40 %	-19.44 %	-17.00 %	-16.90 %
Depreciation & Amortization	-2.56 %	-21.47 %	-2.91 %	-19.44 %	-3.16 %	-10.90 /
Administration costs	-17.86 %	-16.91 %	-11.81 %	-12.70 %	-12.50 %	-12.30 %
R&D costs	-11.70 %	-9.73 %	-9.17 %	-10.97 %	-10.00 %	-9.80 %
Other operating expenses	-3.99 %	-3.31 %	-2.65 %	-2.39 %	-6.33 %	-4.53 %
EBIT	17.79 %	6.53 %	10.58 %	0.43 %	0.02 %	2.00 9
Net financial results	3.72 %	-0.38 %	-0.50 %	-0.52 %	-0.66 %	-0.54 %
EBT	21.51 %	6.15 %	10.09 %	-0.09 %	-0.64 %	1.46 %
Income taxes	-6.80 %	-2.84 %	-6.02 %	-0.44 %	0.19 %	-0.44 %
Net income / loss	14.44 %	3.04 %	4.03 %	-0.77 %	-0.44 %	1.01 %

Dr. Kalliwoda | Research © 2012

8 Balance sheets

alance sheet - Realtech AG

			Fiscal ye	ear		
in EURm	2008	2009	2010	2011	2012E	2013E
Assets						
Cash and cash equivalents	5.32	7.30	6.36	13.22	12.46	12.41
Securities	1.12	0.00	0.00	0.00	0.00	0.00
Trade accounts and notes receivables	24.03	17.99	16.71	9.88	10.38	12.04
Other current assets	1.78	1.74	4.35	4.93	5.18	6.01
Current assets	32.25	27.04	27.42	28.04	28.02	30.46
Property, plant and equipment	9.15	8.98	14.32	13.64	14.14	14.64
Other intangible assets	0.33	0.64	0.62	0.44	0.47	0.54
Goodwill	4.34	4.34	4.33	4.33	4.33	4.33
Other financial assets	0.14	0.15	0.20	0.66	0.69	0.80
Deferred tax assets	0.28	0.22	2.54	2.91	2.96	2.82
Non-current assets	14.23	14.32	22.01	21.98	22.59	23.13
Total assets	46.48	41.35	49.43	50.02	50.61	53.58
Liabilities						
Trade payables	2.34	1.93	1.46	1.36	1.43	1.66
Other liabilities	5.59	4.80	12.08	11.81	12.40	14.39
Short-term leasing debt	0.00	0.00	0.26	0.26	0.27	0.28
Provisions	8.84	5.68	3.04	3.05	3.20	3.71
Current liabilities	16.77	12.41	16.85	16.48	17.30	20.04
Long-term leasing debt	0.00	0.00	5.33	5.14	5.04	4.94
Deferred tax liabilities	0.48	0.38	1.85	1.84	1.90	1.75
Long-term liabilities	0.48	0.38	7.18	6.99	6.94	6.69
Total liabilities	17.25	12.79	24.03	23.47	24.24	26.73
Shareholders equity	28.50	27.79	24.46	25.61	25.43	25.91
Minority interests	0.72	0.78	0.94	0.93	0.93	0.94
Total equity and liabilities	46.48	41.35	49.43	50.02	50.61	53.58

Dr. Kalliwoda | Research $\ensuremath{\textcircled{C}}$ 2012

9 Cash flow statements

	Fiscal year						
in EURm	2008	2009	2010	2011	2012E	2013E	
Net income / loss	5.70	1.20	-1.37	0.81	-0.18	0.48	
Depreciation & Amortization	1.01	1.13	1.15	1.24	1.30	1.51	
Change of working capital	-3.28	5.36	0.81	6.73	-0.08	-0.28	
Others	-0.12	-2.58	1.65	-6.23	0.15	0.51	
Net operating cash flow	3.31	5.11	2.24	2.54	1.19	2.23	
Cash flow from investment	15.67	-0.62	-1.12	4.33	-1.82	-2.08	
Free cash flow	18.98	4.49	1.12	6.88	-0.63	0.14	
Cash flow from financing	-23.55	-2.50	-2.62	-0.05	-0.12	-0.20	
Change of cash	-4.57	1.99	-0.94	6.86	-0.76	-0.05	
Cash at the beginning of the period	9.89	5.32	7.30	6.36	13.22	12.46	
Cash at the end of the period	5.32	7.30	6.36	13.22	12.46	12.41	

Dr. Kalliwoda | Research © 2012

10 Financial ratios


Fiscal year	2008	2009	2010	2011	2012E	2013E	2014E	2015E
Gross margin	39.42%	35.65%	48.37%	46.41%	46.41%	46.41%	46.41%	46.41%
EBITDA margin	11.35%	6.02%	13.50%	3.59%	3.18%	5.16%	6.16%	7.16%
EBIT margin	9.92%	4.18%	10.58%	0.43%	0.02%	2.00%	3.00%	4.00%
Net margin	8.05%	1.95%	-3.48%	2.06%	-0.44%	1.01%	1.77%	2.51%
Return on equity (ROE)	20.01%	4.27%	-5.26%	3.22%	-0.71%	1.88%	3.68%	5.64%
Return on assets (ROA)	9.11%	3.08%	-2.60%	2.03%	0.18%	1.43%	2.20%	3.05%
Return on capital employed (ROCE)	16.17%	4.79%	5.17%	2.83%	0.02%	1.99%	3.38%	4.95%
Net debt (in EURm)	-6.44	-7.30	-0.77	-7.82	-7.15	-7.19	-7.72	-8.85
Net gearing	-22.58%	-26.29%	-3.14%	-30.53%	-28.12%	-27.74%	-28.73%	-31.129
Equity ratio	61.32%	67.19%	49.49%	51.21%	50.25%	48.36%	47.05%	46.50%
Current ratio	1.92	2.18	1.63	1.70	1.62	1.52	1.46	1.44
Quick ratio	1.82	2.04	1.37	1.40	1.32	1.22	1.16	1.14
Net interest cover	-4.78	17.20	21.33	0.82	0.03	3.67	6.59	10.36
Net debt/EBITDA	-0.80	-1.97	-0.14	-5.56	-5.47	-2.92	-2.28	-1.99
Tangible BVPS	4.60	4.44	3.78	3.97	3.92	4.01	4.19	4.48
Capex/Sales	n.a	-2.07%	-16.38%	-0.96%	-4.43%	-4.36%	-4.22%	-4.10%
Working capital/Sales	25.25%	21.10%	19.04%	4.19%	4.19%	4.19%	4.19%	4.19%
EV/Sales	0.25	0.28	0.44	0.45	0.43	0.37	0.32	0.28
EV/EBIT DA	2.18	4.72	3.28	12.44	13.37	7.10	5.18	3.93
EV/EBIT	2.49	6.79	4.19	104.08	2126.60	18.33	10.63	7.04
P/Tangible BVPS	0.92	0.95	1.12	1.07	1.08	1.06	1.01	0.95
P/E	3.90	18.59	-16.40	28.19	-125.37	47.26	23.50	14.61
P/FCF	1.19	5.02	20.10	3.28	-35.57	155.89	34.86	18.16

EBIT margin

Net margin

Return on Assets

2014E





Profitability (%) 21.00 18.00 15.00 12.00 9.00 6.00 3.00 0.00 2008 2009 2010 2011 2012E 2013E 2014E -3.00




Return on Assets


Return on Common Equity





P/Tangible BVPS 1.50 1.25 1.00 0.75 0.50





Source: Company information, Dr. Kalliwoda Research GmbH



14

-6.00

Sales split 2011



Margin development

2011

2012E

2013E

15.00

12.50

10.00

7.50

5.00

2.50

0.00

-2.50

-5.00

2008

2009

DR. KALL	IWODA	Rüsterstraße 4a
RESEARCH	60325 Frankfurt Tel.: 069-97 20 58 53	
KESEARCE	KLSL/ KCH GHIOH	
		www.kalliwoda.com
Primary Research Fair Value A	analysis International Roadshows	
Head:	CEFA-Analyst; University of	Sectors: IT, Sof ware, Electricals &
Dr. Norbert Kalliwoda	Frankfurt/Main; PhD in Economics;	Electronics, Mechanical
E-Mail: nk@kalliwoda.com	DiplKfm.	Engineering, Logistics, Laser,
		Technology, Raw Materials
Dr. Peter Arendarski	Senior-Analyst, Msc & Ph.D in	Sectors: Technology, Raw Materials,
E-Mail: pa@kalliwoda.com	Finance (Poznan Univers. of	Banks & Insurances, Financial-
	Economics),CFA Level 3 Candidate	Modelling (Quant., Buyside)
Patrick Bellmann	Junior-Analyst; WHU - Otto	Sectors: Support Research and
E-Mail: pb@kalliwoda.com	Beisheim School of Management,	Quantitative Approach
	Vallendar (2012)	
Andreas Braun	Junior-Analyst; University of	Sectors: Support Research and
E-Mail: rb@kalliwoda.com	Frankfurt/Main (2012)	Quantitative Approach
Michael John	DiplIng. (Aachen)	Sectors: Chemicals, Chemical
E-Mail: mj@kalliwoda.com		Engineering, Basic Metals,
		Renewable Energies, Laser/Physics
Maximilian F. Kaessens	Bachelor of Science in Business	Sectors: Financials, Real Estate
E-Mail: mk@kalliwoda.com	Administration (Babson College	
	(05/2012), Babson Park, MA (US))	
Adrian Kowollik	DiplKfm.; Humboldt-Universität	Sectors: Media, Internet, Gaming,
E-Mail: ak@kalliwoda.com	zu Berlin, CFA Candidate	Technology, Eastern European
		stocks
Dr. Christoph Piechaczek	DiplBiologist; Technical	Sectors: Biotech & Healthcare;
E-Mail: cp@kalliwoda.com	University Darmstadt; Univ.	Medical Technology Pharmaceutical
Hellenset Calassensel and 14	Witten-Herdecke.	Contract O'I Decement Decement
Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com	DiplGeophysicists; University of Frankfurt/Main.	Sectors: Oil, Regenerative Energies,
E-Mail: IIS@Kailiwoda.com	Frankfurt/Main.	Specialities Chemicals, Utilities
Dr. Erik Schneider	DiplBiologist; Technical	Sectors: Biotech & Healthcare;
E-Mail: es@kalliwoda.com	University Darmstadt; Univ.	Medical Technology Pharmaceutical
	Hamburg.	
David Schreindorfer	MBA, Economic Investment	Sectors: IT/Logistics; Quantitative
E-Mail: ds@kalliwoda.com	Management; Univ. Frankfurt/	Modelling
	Univ. Iowa (US).	
Nele Rave	Lawyer; Native Speaker, German	Legal adviser
E-Mail: nr@kalliwoda.com	School London,	

Also view Sales and Earnings Estimates: DR. KALLIWODA | RESEARCH on Terminals of Bloomberg, Thomson Reuters, vwd group and Factset Analyst of this research: Dr,. Norbert Kalliwoda, CEFA



BUY:	Based on our analysis, we expect the stock to appreciate and produce a total return of at least 10% over the next twelve months
ACCUMULATE:	Based on our analysis, we expect the stock to appreciate and produce a total return between 5%-10% over the next twelve months
HOLD:	Based on our analysis, we expect the stock to produce a total return between -5% and +5% over the next twelve months
REDUCE:	Based on our analysis, we expect the stock to cause a negative return between -5% and -10% over the next twelve months
SELL:	Based on our analysis, we expect the stock to cause a negative return exceeding - 10% over the next twelve months and should be sold

Additional Disclosure

DR.KALLIWODA | RESEARCH GmbH made this analysis on the basis of publicly available sources deemed reliable. We work as reliable as possible. But we cannot take warranty of the balance, precision, accuracy and completeness of the information and opinions.

This study does not replace personal advice. This study is not a solicitation to buy or sell any investment instruments discussed in this study. Therefore DR.KALLIWODA | RESEARCH GmbH advises to consult your bank or financial advisor before any investment-disposition.

In the UK this study is to be distributed only to persons who are described in Section 11 (3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996 (as amended). This study may not be distributed and forwarded directly or indirectly to any other class of persons. The distribution of this document in other international jurisdictions may be restricted by law and persons who possess this study should inform themselves of any existing restrictions and comply with them.

DR.KALLIWODA | RESEARCH GmbH and its employees may hold positions in any securities mentioned in this document or in related investments and may rise or sell these securities or related investments.

Possible conflicts of interest

Neither DR.KALLIWODA | RESEARCH GmbH nor any company affiliated to DR.KALLIWODA | RESEARCH GmbH

a) holds securities that are the subject of this study, in a proportion of 1% or more of the share capital;

b) was involved in issuing securities that are the subject of this study;

c) holds a net selling position in the shares of the analyzed company of at least 1% of the share capital;

d) have been in charge of the analysed securities on the stock exchange or the market based on a contract with the issuer.

DR.KALLIWODA | RESEARCH GmbH holds only with the REALTECH Company a contractual relationship for the preparation of research studies. By accepting this document the reader / recipient agrees with the obligations mentioned in this disclaimer.

DISCLAIMER

The information and opinions in this analysis were prepared by DR. KALLIWODA | RESEARCH GmbH. The information herein is believed by DR. KALLIWODA | RESEARCH GmbH to be reliable and has been obtained from public sources believed to be reliable. With the exception of information about DR. KALLIWODA | RESEARCH GmbH, DR. KALLIWODA | RESEARCH GmbH makes no representation as to the accuracy or completeness of such information.

Opinions, estimates and projections in this report constitute the current judgement of the author as of the date of this analysis. They do not necessarily reflect the opinions, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, except if research on the subject company is withdrawn. Prices and availability of financial instruments also are subject to change without notice. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decision using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives. If a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results.

This report may not be reproduced, distributed or published by any person for any purpose without DR. KALLIWODA | RESEARCH GmbH's prior written consent. Please cite source when quoting.